

Antibody against Chikungunya virus (mRNA-1944)


Last updated: February 5, 2019

Modality	Program #	Program Indication		Preclinical development	Phase 1	Phase 2	Phase 3 and commercial	Moderna rights
 Systemic secreted therapeutics	mRNA-1944	Antibody against Chikungunya virus						Worldwide <i>DARPA funded</i>
	AZD7970	Relaxin <i>Heart failure</i>						50-50 U.S. profit sharing; AZ to pay royalties on ex-U.S. sales
	mRNA-3630	α -GAL <i>Fabry disease</i>						Worldwide

mRNA-1944 currently dosing in healthy volunteers in a Phase 1 study

Antibody against Chikungunya virus (mRNA-1944)


mRNA-encoded antibody for passive immunity against Chikungunya



Antibody against Chikungunya virus (mRNA-1944) as platform proof point for systemic therapeutics

Species:
NHP

Expression of antibody against Chikungunya virus with repeat dosing of mRNA-1944 in non-human primate GLP toxicology study



¹Range for autoimmune and oncology drugs based on pharmacokinetics described in FDA labels for top selling antibody therapies

²Extrapolated from Chik Vaccine mice studies; Source: Yoon I-K, Alera MT, Lago CV, Tac-An IA, Villa D, Fernandez S, et al. (2015) High Rate of Subclinical Chikungunya Virus Infection and Association of Neutralizing Antibody with Protection in a Prospective Cohort in The Philippines. PLoS Negl Trop Dis 9(5): e0003764. doi:10.1371/journal.pntd.0003764


Antibody against Chikungunya virus (mRNA-1944)

Ongoing Phase 1 design

- Randomized, placebo-controlled, single ascending dose study in healthy adults

Key Objectives

- Evaluate safety and tolerability of escalating doses of mRNA-1944 administered via intravenous infusion
- Determine pharmacokinetics of four dose levels (0.1, 0.3, 0.6, 1 mg/kg)
- Determine if the antibodies produced are sufficiently active to neutralize viral infection in assays
- Determine the pharmacodynamics of anti-Chikungunya virus IgG levels



Special note regarding forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s Prospectus filed with the U.S. Securities and Exchange Commission (SEC) on December 7, 2018 and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.